RA
COLL icon

Rise Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Rise Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16
Closed -$560 – 382
2025
Q3 		$560 Buy
+16
New +$556 ﹤0.01% 1389

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rise Advisors's COLL Position: Q4 2025 in Review

Rise Advisors sold out of Collegium Pharmaceutical (COLL) in Q4 2025, closing a stake of 16 shares — an estimated $560 sold.

Rise Advisors first reported a position in COLL in Q3 2025 and held it in 1 quarter. The position peaked at $560 in Q3 2025. 278 funds tracked by Wall St. Rank hold COLL as of Q4 2025.

  • Rise Advisors reported no remaining Collegium Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 16 Collegium Pharmaceutical shares in Q4 2025, an estimated $560.
  • Rise Advisors first reported a position in Collegium Pharmaceutical in Q3 2025 and held it in 1 quarter.
  • Rise Advisors's Collegium Pharmaceutical position peaked at $560 in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.